Report Detail

Request for Sample of this report

Pharma & Healthcare Global UCD Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4742005
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 108 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global UCD Therapeutics market size was valued at US$ 756 million in 2025 and is forecast to a readjusted size of US$ 1437 million by 2032 with a CAGR of 10.5% during review period.
UCD therapeutics are prescription medicines used to treat inherited metabolic diseases caused by deficiencies in urea-cycle enzymes or related transport proteins. These therapies reduce ammonia and other toxic metabolites by establishing alternative nitrogen-excretion pathways, activating residual urea-cycle function, replacing deficient enzyme activity or restoring the underlying genetic function, thereby reducing hyperammonemic crises and neurological injury. Major products include glycerol phenylbutyrate, sodium phenylbutyrate, intravenous sodium phenylacetate and sodium benzoate, carglumic acid, pegylated arginase, as well as investigational gene therapies, mRNA therapies and gene-editing treatments. Key upstream inputs include phenylbutyric acid and its derivatives, glycerol, sodium benzoate, carglumic acid API, recombinant cell lines, culture media, purification resins, PEG-modification reagents, plasmids, AAV vectors, nucleotides, lipid nanoparticle materials, sterile excipients and pharmaceutical packaging. Major downstream channels include inherited-metabolic-disease centers, children's hospitals, general hospitals, specialty pharmacies and rare-disease distributors. The industry is characterized by a limited patient population, high treatment value per patient, strict long-term adherence requirements and substantial regulatory barriers, with an estimated blended gross margin of approximately 70%–84%.
From the demand perspective, the UCD therapeutics market is expected to maintain steady growth, supported by broader newborn screening, wider use of genetic testing, expansion of inherited-metabolic-disease networks and longer patient survival. Improved identification of late-onset, mild and atypical cases will increase the number of patients receiving long-term treatment. Current demand remains concentrated in nitrogen scavengers and medicines for acute hyperammonemic crises, while subtype-specific therapies for conditions such as NAGS deficiency and ARG1 deficiency are increasing treatment value per patient. Greater availability of rare-disease medicines, local production and reimbursement support in emerging markets will also improve global treatment access.
From a product perspective, nitrogen scavengers will remain the foundation of treatment for most patients in the foreseeable future, although innovation is shifting from chronic metabolic control toward subtype-specific and disease-modifying therapies. Competition among conventional products will increasingly focus on palatability, formulation convenience, dosing burden, pediatric suitability and long-term adherence. Enzyme-replacement therapies may establish clearer clinical positions in patients with specific enzymatic deficiencies. At the same time, gene therapy, mRNA therapy and in vivo gene-insertion approaches are seeking to restore sustained expression of urea-cycle enzymes and could materially reduce dietary restrictions and lifelong dependence on nitrogen-scavenger therapy if durable efficacy and acceptable safety are demonstrated.
From the competitive perspective, the commercial market remains concentrated among a limited number of companies with established nitrogen-scavenger brands, rare-disease distribution channels and specialized patient-support capabilities. The entry of conventional and authorized generics will increase pricing and market-share pressure on premium brands, although originator products with differentiated formulations, pediatric advantages and strong global access capabilities may retain meaningful positions. Competition will gradually shift from simple ammonia reduction toward prevention of hyperammonemic crises, improvement of neurological outcomes, reduction of hospitalization and better quality of life. Companies combining genetic-medicine platforms, rare-disease commercialization capabilities and long-term patient follow-up systems are likely to gain an advantage in the next stage of market development.
From the risk perspective, individual UCD subtypes have small patient populations and highly variable clinical presentations, making trials vulnerable to limited enrollment, natural disease fluctuation and complex endpoint selection. Gene therapies may face immune responses, liver-safety concerns, declining efficacy during pediatric liver growth and limited repeat-dosing options, while mRNA therapies must address repeated intravenous administration and long-term delivery-system tolerability. High-cost one-time treatments will also face close scrutiny regarding affordability, durability and outcome-based payment arrangements. Over the longer term, the market is expected to develop into a mixed structure of conventional nitrogen scavengers, subtype-specific medicines and disease-modifying therapies, with long-term efficacy, treatment burden, affordability and lifecycle patient management becoming the main determinants of product value.
Report Scope
This report is a detailed and comprehensive analysis for global UCD Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global UCD Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global UCD Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global UCD Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global UCD Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for UCD Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global UCD Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Ucyclyd Pharma, Recordati, Immedica Pharma, MPerium, Medunik, Zevra Therapeutics, Mallinckrodt, Lupin, Grand Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
UCD Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Nitrogen Scavengers
Urea Cycle Activators
Enzyme Therapies
Other
Market segment by Active Ingredient
Glycerol Phenylbutyrate
Sodium Phenylbutyrate
Sodium Phenylacetate and Benzoate
Carglumic Acid
Other
Market segment by Administration Route
Oral
Intravenous
Subcutaneous
Market segment by Application
Hospital
Clinic
Other
Market segment by players, this report covers
Amgen
Ucyclyd Pharma
Recordati
Immedica Pharma
MPerium
Medunik
Zevra Therapeutics
Mallinckrodt
Lupin
Grand Pharmaceutical Group
Lee's Pharmaceutical Holdings
Winhealth Pharma Group
Ultragenyx
Arcturus Therapeutics
iECURE
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe UCD Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of UCD Therapeutics, with revenue, gross margin, and global market share of UCD Therapeutics from 2021 to 2026.
Chapter 3, the UCD Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and UCD Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of UCD Therapeutics.
Chapter 13, to describe UCD Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of UCD Therapeutics by Type
    • 1.3.1 Overview: Global UCD Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global UCD Therapeutics Consumption Value Market Share by Type in 2025
    • 1.3.3 Nitrogen Scavengers
    • 1.3.4 Urea Cycle Activators
    • 1.3.5 Enzyme Therapies
    • 1.3.6 Other
  • 1.4 Classification of UCD Therapeutics by Active Ingredient
    • 1.4.1 Overview: Global UCD Therapeutics Market Size by Active Ingredient: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global UCD Therapeutics Consumption Value Market Share by Active Ingredient in 2025
    • 1.4.3 Glycerol Phenylbutyrate
    • 1.4.4 Sodium Phenylbutyrate
    • 1.4.5 Sodium Phenylacetate and Benzoate
    • 1.4.6 Carglumic Acid
    • 1.4.7 Other
  • 1.5 Classification of UCD Therapeutics by Administration Route
    • 1.5.1 Overview: Global UCD Therapeutics Market Size by Administration Route: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global UCD Therapeutics Consumption Value Market Share by Administration Route in 2025
    • 1.5.3 Oral
    • 1.5.4 Intravenous
    • 1.5.5 Subcutaneous
  • 1.6 Global UCD Therapeutics Market by Application
    • 1.6.1 Overview: Global UCD Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Clinic
    • 1.6.4 Other
  • 1.7 Global UCD Therapeutics Market Size & Forecast
  • 1.8 Global UCD Therapeutics Market Size and Forecast by Region
    • 1.8.1 Global UCD Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global UCD Therapeutics Market Size by Region, (2021-2032)
    • 1.8.3 North America UCD Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.4 Europe UCD Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific UCD Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.6 South America UCD Therapeutics Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa UCD Therapeutics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Amgen
    • 2.1.1 Amgen Details
    • 2.1.2 Amgen Major Business
    • 2.1.3 Amgen UCD Therapeutics Product and Solutions
    • 2.1.4 Amgen UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Amgen Recent Developments and Future Plans
  • 2.2 Ucyclyd Pharma
    • 2.2.1 Ucyclyd Pharma Details
    • 2.2.2 Ucyclyd Pharma Major Business
    • 2.2.3 Ucyclyd Pharma UCD Therapeutics Product and Solutions
    • 2.2.4 Ucyclyd Pharma UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Ucyclyd Pharma Recent Developments and Future Plans
  • 2.3 Recordati
    • 2.3.1 Recordati Details
    • 2.3.2 Recordati Major Business
    • 2.3.3 Recordati UCD Therapeutics Product and Solutions
    • 2.3.4 Recordati UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Recordati Recent Developments and Future Plans
  • 2.4 Immedica Pharma
    • 2.4.1 Immedica Pharma Details
    • 2.4.2 Immedica Pharma Major Business
    • 2.4.3 Immedica Pharma UCD Therapeutics Product and Solutions
    • 2.4.4 Immedica Pharma UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Immedica Pharma Recent Developments and Future Plans
  • 2.5 MPerium
    • 2.5.1 MPerium Details
    • 2.5.2 MPerium Major Business
    • 2.5.3 MPerium UCD Therapeutics Product and Solutions
    • 2.5.4 MPerium UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 MPerium Recent Developments and Future Plans
  • 2.6 Medunik
    • 2.6.1 Medunik Details
    • 2.6.2 Medunik Major Business
    • 2.6.3 Medunik UCD Therapeutics Product and Solutions
    • 2.6.4 Medunik UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Medunik Recent Developments and Future Plans
  • 2.7 Zevra Therapeutics
    • 2.7.1 Zevra Therapeutics Details
    • 2.7.2 Zevra Therapeutics Major Business
    • 2.7.3 Zevra Therapeutics UCD Therapeutics Product and Solutions
    • 2.7.4 Zevra Therapeutics UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Zevra Therapeutics Recent Developments and Future Plans
  • 2.8 Mallinckrodt
    • 2.8.1 Mallinckrodt Details
    • 2.8.2 Mallinckrodt Major Business
    • 2.8.3 Mallinckrodt UCD Therapeutics Product and Solutions
    • 2.8.4 Mallinckrodt UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Mallinckrodt Recent Developments and Future Plans
  • 2.9 Lupin
    • 2.9.1 Lupin Details
    • 2.9.2 Lupin Major Business
    • 2.9.3 Lupin UCD Therapeutics Product and Solutions
    • 2.9.4 Lupin UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Lupin Recent Developments and Future Plans
  • 2.10 Grand Pharmaceutical Group
    • 2.10.1 Grand Pharmaceutical Group Details
    • 2.10.2 Grand Pharmaceutical Group Major Business
    • 2.10.3 Grand Pharmaceutical Group UCD Therapeutics Product and Solutions
    • 2.10.4 Grand Pharmaceutical Group UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Grand Pharmaceutical Group Recent Developments and Future Plans
  • 2.11 Lee's Pharmaceutical Holdings
    • 2.11.1 Lee's Pharmaceutical Holdings Details
    • 2.11.2 Lee's Pharmaceutical Holdings Major Business
    • 2.11.3 Lee's Pharmaceutical Holdings UCD Therapeutics Product and Solutions
    • 2.11.4 Lee's Pharmaceutical Holdings UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Lee's Pharmaceutical Holdings Recent Developments and Future Plans
  • 2.12 Winhealth Pharma Group
    • 2.12.1 Winhealth Pharma Group Details
    • 2.12.2 Winhealth Pharma Group Major Business
    • 2.12.3 Winhealth Pharma Group UCD Therapeutics Product and Solutions
    • 2.12.4 Winhealth Pharma Group UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Winhealth Pharma Group Recent Developments and Future Plans
  • 2.13 Ultragenyx
    • 2.13.1 Ultragenyx Details
    • 2.13.2 Ultragenyx Major Business
    • 2.13.3 Ultragenyx UCD Therapeutics Product and Solutions
    • 2.13.4 Ultragenyx UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Ultragenyx Recent Developments and Future Plans
  • 2.14 Arcturus Therapeutics
    • 2.14.1 Arcturus Therapeutics Details
    • 2.14.2 Arcturus Therapeutics Major Business
    • 2.14.3 Arcturus Therapeutics UCD Therapeutics Product and Solutions
    • 2.14.4 Arcturus Therapeutics UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Arcturus Therapeutics Recent Developments and Future Plans
  • 2.15 iECURE
    • 2.15.1 iECURE Details
    • 2.15.2 iECURE Major Business
    • 2.15.3 iECURE UCD Therapeutics Product and Solutions
    • 2.15.4 iECURE UCD Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 iECURE Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global UCD Therapeutics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of UCD Therapeutics by Company Revenue
    • 3.2.2 Top 3 UCD Therapeutics Players Market Share in 2025
    • 3.2.3 Top 6 UCD Therapeutics Players Market Share in 2025
  • 3.3 UCD Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 UCD Therapeutics Market: Region Footprint
    • 3.3.2 UCD Therapeutics Market: Company Product Type Footprint
    • 3.3.3 UCD Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global UCD Therapeutics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global UCD Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global UCD Therapeutics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global UCD Therapeutics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America UCD Therapeutics Consumption Value by Type (2021-2032)
  • 6.2 North America UCD Therapeutics Market Size by Application (2021-2032)
  • 6.3 North America UCD Therapeutics Market Size by Country
    • 6.3.1 North America UCD Therapeutics Consumption Value by Country (2021-2032)
    • 6.3.2 United States UCD Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada UCD Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico UCD Therapeutics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe UCD Therapeutics Consumption Value by Type (2021-2032)
  • 7.2 Europe UCD Therapeutics Consumption Value by Application (2021-2032)
  • 7.3 Europe UCD Therapeutics Market Size by Country
    • 7.3.1 Europe UCD Therapeutics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany UCD Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.3 France UCD Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom UCD Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia UCD Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy UCD Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific UCD Therapeutics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific UCD Therapeutics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific UCD Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific UCD Therapeutics Consumption Value by Region (2021-2032)
    • 8.3.2 China UCD Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan UCD Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea UCD Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.5 India UCD Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia UCD Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia UCD Therapeutics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America UCD Therapeutics Consumption Value by Type (2021-2032)
  • 9.2 South America UCD Therapeutics Consumption Value by Application (2021-2032)
  • 9.3 South America UCD Therapeutics Market Size by Country
    • 9.3.1 South America UCD Therapeutics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil UCD Therapeutics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina UCD Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa UCD Therapeutics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa UCD Therapeutics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa UCD Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa UCD Therapeutics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey UCD Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia UCD Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE UCD Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 UCD Therapeutics Market Drivers
  • 11.2 UCD Therapeutics Market Restraints
  • 11.3 UCD Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 UCD Therapeutics Industry Chain
  • 12.2 UCD Therapeutics Upstream Analysis
  • 12.3 UCD Therapeutics Midstream Analysis
  • 12.4 UCD Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on UCD Therapeutics. Industry analysis & Market Report on UCD Therapeutics is a syndicated market report, published as Global UCD Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of UCD Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo